Friday, May 15, 2009
FRIDAY, May 15 (HealthDay News) -- In patients with stage II colon cancer, a new genomic test -- the Oncotype DX colon assay -- can accurately predict the risk of recurrence, according to research to be presented May 30 at the annual meeting of the American Society of Clinical Oncology, held from May 29 to June 2 in Orlando, Fla.
David Kerr, M.D., of the University of Oxford in the United Kingdom, and colleagues conducted four development studies in which they analyzed 761 genes from 1,851 patients with stage II colon cancer and identified 18 genes -- including seven prognostic genes, six predictive genes, and five reference genes -- associated with cancer recurrence and treatment response. They subsequently conducted an evaluation study of the Oncotype DX colon assay in another 1,436 patients.
The researchers met their primary goal of validating a score that predicts the risk of colon cancer recurrence. But they did not meet their secondary goal of validating a score that predicts response to 5-fluorouracil and leucovorin after colon cancer surgery.
"Having this well-validated molecular signature to predict risk of colon cancer recurrence will have a significant impact on the way we treat patients with this disease," Kerr said in a statement. "This assay gives physicians important clinical information that will enable them to better select the right patients for the right treatment at the right time."
Diabetes & Endocrinology
Copyright © 2009 ScoutNews, LLC. All rights reserved.